The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
MSCs demonstrate efficacy in preventing both aGVHD and cGVHD following HSCT, particularly in moderate to severe forms. A dose range of 1 × 10⁶ to < 4 × 10⁶ cells/kg was associated with optimal prophylactic outcomes. For SR-aGVHD, MSC infusion resulted in significantly higher remission rates compared to conventional treatments, especially in severe cases.
Authors
- Wenhui Zeng (ORCID: https://orcid.org/0000-0002-3482-9269)
- Junsong Ye (ORCID: https://orcid.org/0000-0003-4336-1933)
- Zhengwei Zou
- An Xie (ORCID: https://orcid.org/0000-0002-8806-1662)
- Cixiang Chen
- Shuzhou Wu
- Nan Wu
- Lincai Li
- Lin Zhou
- Jiabing Wang
Institutions
- Jiangnan University (CN)
- Ganzhou People's Hospital (CN)
- Gannan Medical University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Jiangxi University of Science and Technology (CN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1186/s13287-026-04955-0
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00